Episode Details
Back to Episodes
TheraCryf Extends IP to 2046 as OX1 Nears Clinical Milestone | The Watchlist
Episode 129
Published 6 months, 1 week ago
Description
In this episode, we speak with Huw Jones, CEO of TheraCryf (AIM: TCF), about the company’s latest progress advancing its lead asset OX1 toward clinical readiness. Listeners will hear how a newly secured process patent could extend exclusivity to 2046, alongside successful GMP manufacturing that demonstrates scalability and operational readiness.
This discussion covers:
- OX1’s role in addressing substance use disorders and its growing market opportunity
- The strategic importance of extending patent protection to 2046
- Achieving GMP manufacturing and exceeding production targets
- Scaling capabilities as TheraCryf approaches clinical trials
- How IP and manufacturing alignment strengthens partnership potential
Website: https://theracryf.com
This podcast is made in partnership with TheraCryf. This podcast is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://stockhouse.com/legal/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.